First line oral vinorelbine in elderly patients with advanced non-small-cell lung cancer


Summary

Purpose: The activity of vinorelbine (VRL) as single agent in treatment-naïve inoperable non small cell cancer (NSCLC) patients (pts) has been assessed in several published studies. Oral and intravenous formulation have a linearity of VRL pharmacokinetics with both routes of administration. This is a study with oral VRL in first line advanced NSCLC in elderly pts.

Patients and methods: A total of 12 chemonaive elderly pts ≥70 years were recruited from October 2005 through to June 2006. Principal inclusion criteria included histologically confirmed advanced NSCLC, performance status ≤2, measurable disease, appropriate bone marrow and organ function. The dosage schedule was 60 mg/m² once a week for three weeks (first cycle), followed if not toxicity by 80 mg/m² once a week, until disease progression or development of unacceptable toxicity.

Results: The mean age was 74 years (range: 71 to 79), all males, and all pts stage IV. Histology subtypes: adenocarcinoma in 5 pts, large cell carcinoma in 1 pts and squamous cell carcinoma in 6 pts. PS (ECOG) distribution was: 3 pts with PS 1, and 9 pts with PS 2. The median weekly VRL doses was 13 (range 3-23). Out of 11 pts receiving the second cycle, 7 patients went a dose escalation to 80 mg/m². The other 4 pts remained at the 60 mg/m² dose level. There were no complete responses (CR). Two (13%) of 12 patients achieved partial response (PR). There were 6 (50%) stable disease (SD) and 4 (34%) progressive disease (PD). Respect survival, the median follow-up was 4 months (range 1-9 months). Until date, the median survival time (MST) and median progression-free survival had not been reached; and survival and progression-free survival was 66% in both. Treatment with oral VRL in elderly patients was well tolerated, and there were no toxic deaths. No grade 4 toxicities were observed, and grade 3 toxicities were infrequent, exclusively neutropenia in 2 patients and asthenia in other 2 patients. Rest of toxicities were grade 1 or 2.

Conclusions: Oral VRL appears to be a reasonable alternative intravenous VRL, both in terms of activity and tolerability in advanced, elderly NSCLC patients.

Key words: Chemotherapy. Oral vinorelbine. Elderly. Non small cell lung cancer.

Oncología, 2007; 30 (1):12-20
Introduction

More than 1.3 million new cases of lung cancer occur worldwide every year. In the United States and in Western Europe, lung cancer is the most frequent cause of death among malignant tumors. Non-small cell lung cancer (NSCLC) represents 70-80% of patients with lung cancer. Treatment of these patients is a particular challenge in oncology because more than one third of patients have distant metastases at diagnosis allowing only palliative treatment. Several meta-analyses using data from multiple randomized trials indicated that chemotherapy significantly improves survival and symptom control compared with best supportive care in stage IV NCSLC patients. Also, the 1-year survival rate was increased from 15% to 25%, with an improvement in patient quality of life. However, substantial toxicity impairs the advantages in survival and symptom control of cisplatin-containing regimens. Since the 1990s, new agents were investigated in this setting; these agents include the nucleoside analog gemcitabine (GEM), the vinca-alkaloid vinorelbine (VRL), the taxanes paclitaxel and doce-
taxel the camptothecin-derivatives irinotecan and topotecan.

Vinorelbine is a new semi-synthetic vinca alkaloid which, as with its congeners, has a mechanism-of-action of inhibiting the polymerization of microtubules in the mitosis stage of cell replication\textsuperscript{4, 5}. However, in pre-clinical studies, VRL appears to be more active than vinblastine and vincristine in murine tumors as well as in human tumor xenografts\textsuperscript{6}. Also, its more favorable therapeutic index has been confirmed in clinical practice. Pharmaco-kinetic studies indicate avid tissue uptake (especially in lung tissue), and other pre-clinical data suggest less neuro-toxicity because it has a lesser effect on axonal micro-tubules compared to other vinca alkaloids\textsuperscript{7-9}.

The activity of VRL as single agent in treatment-naïve inoperable NSCLC has been assessed in several published studies. There have been 5 published Phase II trials comprising a total of 247 patients. The cumulative response rate was 26\% (range 12-39\%)\textsuperscript{10-14}. Also, there have been 4 large randomized studies comparing VRL with others schedules. The sample comprised a total of 503 patients treated with VRL and the overall response was 14\% (range 12-15\%)\textsuperscript{15-18}. There has been a significant benefit in survival when comparing monotherapy VRL with best-supportive-care in metastatic first-line NSCLC \textsuperscript{19}. In a randomized phase III trial (Multicenter Italian Lung Cancer in the Elderly Study [MILES]), the combination of GEM and VRL was not more effective than single-agent GEM or VRL in elderly patients \(\geq 70\) years with advanced NSCLC\textsuperscript{20}. In base of this trial, ASCO recommendation for elderly or performance status (PS) 2, support the use of single-agent chemotherapy\textsuperscript{21}.

The initial oral formulations of VRL included a powder-filled capsule and a first-generation soft-gelatin capsule. Clinical studies of this first soft-gelatin capsule showed the feasibility of oral administration of VRL\textsuperscript{22}. The activity of oral VRL in NSCLC\textsuperscript{23} and in advanced breast cancer\textsuperscript{24} seemed to be comparable to intravenous VRL. Oral vinorelbine started in 1994 with a phase I dose-finding study in patients with advanced breast cancer\textsuperscript{25}. The maximum tolerated dose was 100 mg/m\textsuperscript{2} weekly, and the recommended dose for further clinical investigations was 80 mg/m\textsuperscript{2} weekly. Dose-limiting toxicities included neutropenia, nausea/vomiting and constipation due to autonomic neuropathy. Based on the linearity of VRL pharmacokinetics with both routes of administration\textsuperscript{25}, it was established that the oral dose of 80 mg/m\textsuperscript{2} corresponds to the intravenous dose of 30 mg/m\textsuperscript{2}, and the oral dose of 60 mg/m\textsuperscript{2} is comparable to the intravenous dose of 25 mg/m\textsuperscript{2}. Therefore, phase II studies of single-agent oral VRL were conducted in NSCLC and advanced breast cancer, the two major indications for the intravenous form. The initial phase II study of oral VRL [26] in chemotherapy-naïve NSCLC patients used a weekly dose of 80 mg/m\textsuperscript{2}, the dose recommended in the phase I dose-finding study\textsuperscript{25}. This trial was prematurely stopped because of excessive hematological toxicity\textsuperscript{26}. In consequence, a multicenter study was initiated to investigate a new schedule of oral VRL with an intrapatient dose escalation from 60 to 80 mg/m\textsuperscript{2}/week.

In a recent randomized phase II trial of oral vs. intravenous VRL, the activity of oral and intravenous VRL in advanced NSCLC appears to be comparable and the safety profiles of both formulations look qualitatively similar\textsuperscript{27}. We show the experience in only one centre with treatment based on oral VRL as single agent in first line advanced NSCLC in elderly patients more than 70 years.

Patients and Methods

Patient eligibility

Patients recruited into this study were required to have histologically confirmed non-small cell lung cancer. All patients were to have measurable disease target lesions on physical examination (photographs), or computed tomography (CT). Other eligibility criteria were age \(\geq 70\) years, World Health Organization (WHO) performance status (PS) \(\leq 2\) with a life expectancy \(>3\) months, adequate bone marrow reserve (absolute granulocyte count, \(>1,500/\mu\text{L}\); platelet count, \(>100,000/\mu\text{L}\); hemoglobin level, \(>10\ g/\text{dL}\), as well as adequate renal and hepatic function (serum creatinine, AST, ALT and bilirubin levels \(<1.25\ times\ the\ upper\ limit\ of\ normal\)). Exclusion criteria were the presence of other concomitant or metachronous cancers, brain or leptomeningal metastases, radiation to the only measurable disease or within 4 weeks of starting chemotherapy, a pre-
vious chemotherapy regimen, simultaneous infection disease or polyneuropathy, severe cardiac arrhythmia or heart failure, pregnancy or breast feeding.

**Pre-treatment evaluation**

Baseline assessments included medical history, physical examination, complete blood cell count and chemistry profiles to evaluate liver and renal function. Disease extent was quantified by CT scan of thorax and upper abdomen, and photographs of any metastatic skin lesions. All measurable disease was evaluated at least for 4 weeks before inclusion in the study. Bone scintigraphy or a brain CT scan was performed if clinically necessary and bone radiography was limited to suspected areas indicated by radio-nuclide scan. Laboratory tests: blood cell count were performed weekly before each chemotherapy cycle and biochemistry test every 3-4 weeks.

**Drug administration protocol**

VRL was administered on a weekly basis and continued until there was evidence of either disease progression, excessive toxicity or patient refusal. Oral VRL was supplied as 20 mg or 30 mg softgelatin capsules. All doses were taken with a glass of water after a meal. Primary prophylaxis with antiemetics was recommended with metoclopramide, about 30 minutes before VRL intake. In case of nausea/vomiting, we recommended more doses of metoclopramide. If despite metoclopramide, nausea/vomiting still occurred, a 5-HT3 antagonist, oral granisetron was used. Granulocyte colony-stimulating factors were allowed after the first course of treatment in patients with fever accompanying grade 3-4 neutropenia, or in case of asymptomatic grade 4 neutropenia lasting for at least five days. The use of erythropoietin was allowed in the protocol.

Complete blood cell count was checked on the day of each planned treatment. Every 3-4 weeks, a liver function test (AST and ALT) and other biochemistry test was also determined. If granulocyte count was below 1500/µL, platelet count was below 75000 per mm³, or AST/ALT was over 100 IU l on day of each cycle, VRL administration was delayed by a week. Toxicity evaluations were based on the National Cancer Institute’s Common Toxicity Criteria (NCI-CTC), Version 3.0. Dosing was adjusted according to the haematological tolerance of the first three administrations at 60 mg/m²/week. If during this phase, no grade 4 neutropenia or no more than one episode of grade 3 neutropenia occurred, the dose was increased to 80 mg/m² in subsequent administrations, otherwise therapy was continued with 60 mg/m². In case of grade 3 asthenia or poor tolerance in the first three administrations with 60 mg/m² in this special population of elderly patients, most of them with no good performance status, we did not increased to 80 mg/m². If during subsequent treatment at 80 mg/m², grade 4 neutropenia or at least two consecutive episodes of grade 3 neutropenia occurred, the dose was reduced to 60 mg/m² for the subsequent administrations. In case of peripheral neuropathy ≥ grade 3, the administration of vinorelbine had to be held and a new examination had to be performed one week later. If the treatment could not be administered after a three-week interval because of hematological or neurologic toxicity, or other severe toxicities that made it difficult to continue the protocol treatment, we discontinued VRL.

**Treatment evaluation**

Patients who had received ≥ 3 administrations were considered assessable for response and toxicities. Radiological and/or photographic evaluations were repeated every 3 cycles to evaluate response to chemotherapy. Responses to treatment were defined according to RECIST criteria.27

**Statistical analysis**

The primary objective of this trial was to define the activity of oral VRL in elderly patients with advanced NSCLC. Overall survival and failure free survival of this sequential schedule were performed using the Kaplan-Meier estimation method. Survival was defined as the time between initiation of treatment and death. If death had not occurred, survival time was considered censored at the last follow-up time. Failure free survival was defined as the time between initiation of treatment and failure (i.e., death or disease progression). If failure had not occurred at the time of this analysis, failure free survival was considered censored at the time of the last follow-up.
Results

Between October 2005 and June 2006, 12 elderly patients ≥ 70 with advanced NSCLC were included in this study. All of them were evaluable for toxicity and response. Patients’ characteristics on entry into the trial are summarized in Table I. The mean age of the patients was 74 years (range: 71 to 79) with 12 (100%) males and 0 females. Histology types were: adenocarcinoma in 5 patients (42%), large cell carcinoma in 1 patient (8%) and squamous cell carcinoma in 6 patients (50%). The majority of the patients had ECOG PS of 2, 9 patients (75%), 3 patients with PS 1 (25%), and no patients had PS 0. The staging was all 12 patients (100%) with stage IV and no patients with stage IIIB.

TABLE I
Characteristics of the patients on entry into the study

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>12</td>
</tr>
<tr>
<td>Gender:</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12</td>
</tr>
<tr>
<td>Female</td>
<td>0</td>
</tr>
<tr>
<td>Age (years):</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>74</td>
</tr>
<tr>
<td>Range</td>
<td>71-79</td>
</tr>
<tr>
<td>Histology:</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>5</td>
</tr>
<tr>
<td>Large cell</td>
<td>1</td>
</tr>
<tr>
<td>Squamous</td>
<td>6</td>
</tr>
<tr>
<td>Mixed adeno-squamous</td>
<td>0</td>
</tr>
<tr>
<td>Performance status</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>9</td>
</tr>
</tbody>
</table>

Efficacy and survival

A total of 153 oral doses of VRL were administered. The median number of weekly VRL cycles was 13 (range 3-23). Five patients received six cycles or more. Nine patients had at least one administration delayed, but these delays never exceeded 8 days. Fourteen administrations were skipped because of haematological toxicity (65%) or bad conditions (35%). Only 1 patient received only three administrations (one cycle). Out of 11 patients receiving the second cycle, 7 patients underwent a dose escalation to 80 mg/m². The other 4 patients remained at the 60 mg/m² dose level: due to two episodes of grade 2 neutropenia (1 patient), and for the remaining three patients, reasons for not increasing the dose were doubt to the general conditions, and other toxicities as asthenia, gastrointestinal poor tolerance. In addition, in only 1 patient, the weekly doses had to be reduced from 80 to 60 mg/m².

Response rates are shown in Table II. There were no complete responses (CR); 2 (13%) of 12 patients achieved partial response (PR) to oral VRL. There were 6 (50%) stable disease (SD), and 4 (34%) progressive disease (PD). Respect survival, the median follow-up was 4 months (range 1-9 months). Until date, the median survival time (MST) and median progression-free survival had not been reached, and the percentage of patients lived and patients without progression until date was 66% in both respectively. Survival and progression-free survival curves are represented in Figures 1, 2.

TABLE II
Best response to therapy

<table>
<thead>
<tr>
<th>Response</th>
<th>N patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR</td>
<td>2 (16)</td>
</tr>
<tr>
<td>SD</td>
<td>6 (50)</td>
</tr>
<tr>
<td>PD</td>
<td>4 (34)</td>
</tr>
</tbody>
</table>

Toxicity

Treatment with oral VRL in elderly patients was well tolerated, and there were no toxic deaths. Toxicity is represented in Table III. No grade 4 toxicities were observed, and grade 3 toxicities were infrequent, exclusively neutropenia in 2 patients and asthenia in other 2 patients. Rest of toxicities were grade 1 or 2.

There were only 2 patient (17%) who experienced grade 2 anaemia not requiring packed red cells transfusion and 4 patient (32%) developed grade 1 anaemia. No thrombocytopenia was observed. Five patients (41%) had grade 1 neutropenia and no patients had grade 2 neutropenia. Nonhematologic toxicity was also mild and above all asthenia, anorexia and constipation. Grade 2 Vomiting occurred in 4 patients (33%), and grade 1 in other 4 patients.
Diarrhoea was somewhat more in common. Grade 2 asthenia was reported in 2 patients (16%), and grade 1 in 5 patients (41%). Anorexia grade 2 in 5 patients (41%), and grade 1 in 4 patients (33%). Neurosensory symptoms grade 2 were reported in 3 patients (25%), and grade 1 in only 1 patient (8%). Constipation grade 2 was observed in 4 patients (33%), and grade 1 in 5 patients (41%). There were no relevant changes in the hepatic and renal function tests (Table III).

### Table III

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>G1</th>
<th>G2</th>
<th>G3</th>
<th>G4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin</td>
<td>4 (32%)</td>
<td>2 (17%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Platelets</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>5 (41%)</td>
<td>0</td>
<td>2 (16%)</td>
<td>0</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>4 (33%)</td>
<td>4 (33%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Alopecia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Asthenia</td>
<td>5 (41%)</td>
<td>2 (16%)</td>
<td>2 (16%)</td>
<td>0</td>
</tr>
<tr>
<td>Anorexia</td>
<td>4 (33%)</td>
<td>5 (41%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fever</td>
<td>3 (25%)</td>
<td>1 (8%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Infection</td>
<td>0</td>
<td>2 (17%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>5 (41%)</td>
<td>4 (33%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2 (16%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mucositis</td>
<td>1 (8%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2 (16%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neurologic</td>
<td>1 (8%)</td>
<td>3 (25%)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
Discussion

Currently, standard therapy for advanced NSCLC results in overall response of 20-40%, MST of 8-10 months, 1- and 2- year survival rates of 30-35 and 10-15%, respectively, and only a few patients are considered long-term survivors1, 2. Although the high prevalence of NSCLC in older people is clear, elderly subjects are under-represented in clinical trials. This under-representation may be a reflection of largely accepted concepts on the low benefit/risk ratio of chemotherapy in elderly patients. It is recognised that this subpopulation are less aggressively treated and more likely to be offered no systemic treatment29. Earle et al30 noted that only 22% of those aged 65 years or over received any chemotherapy. Among the 6232 elderly patients with NSCLC in the Surveillance, Epidemiology and End-Results (SEER) registry of the NCI, median survival was 30 weeks for patients treated with chemotherapy, but only 23 weeks for those receiving supportive care alone.

VRL has been evaluated in elderly patients with advanced NSCLC in a randomised trial, the ELVIS trial19, in which intravenous VRL had a significant advantage compared with best supportive care in advanced patients ≥70 years. Their median survival was 28 weeks compared with 21 weeks for patients on best supportive care (P=0.03). The one-year survival rate was also in favour of the VRL-treated patients: 32% versus 14%, and improvement in quality of life.

Enhancing the importance of VRL in this population of patients, the MILES trial recently reported that monotherapy with either VRL or GEM is equivalent to combination therapy with both drugs [20]. This 698-patient trial examined multiple endpoints, including tumor response rate, time to progression, survival, and quality of life and observed no statistically significant differences between the single agents and the combination. The response rate in this trial with intravenous VRL was 18%. This findings justified the investigation of single agent chemotherapy in elderly patients with metastatic NSCLC.

In a recent randomized phase II trial of oral vs. intravenous VRL designed to determine the efficacy and safety of oral VRL in previously untreated patients with advanced NSCLC, ninety-eight patients were assessable. The response rates in evaluable patients were 14% in the oral arm and 12% in the intravenous arm. The median progression-free survival with oral and intravenous VRL was 3.2 months and 2.1 months, respectively, and the median survival 9.3 and 7.9 months, respectively. The most common haematological toxicity was neutropenia, which was grade 3-4 in 46% of patients and for 7% of administrations in the oral arm, and in 62% of patients and for 25% of administrations in the intravenous arm. Non-haematological toxicities including nausea, vomiting, anorexia, weight loss, diarrhoea and constipation were generally mild to moderate. So, the conclusion was that the activity of oral and intravenous VRL in advanced NSCLC appears to be comparable. The safety profiles of both formulations look qualitatively similar. Oral VRL can therefore be considered a good alternative to intravenous administration27.

Age is associated with physiologic modifications that affect drug pharmacokinetics and metabolism. Therefore, knowledge of pharmacokinetics in elderly patients is one of the major factors in deciding whether or not to reduce the dose to prevent toxicity. The study by Puozzo et al31 evaluated the influence of age on oral VRL pharmacokinetics in elderly patients with non-small-cell lung cancer (NSCLC), and compared with a reference population selected from VRL pharmacokinetic database. There was no difference between pharmacokinetic parameters, including the bioavailability factor and a similar interindividual variability between the 2 groups. Furthermore, no correlation between age and oral VRL total clearance was observed. Therefore, no requirement for oral VRL dose reduction in elderly population was suggested from a pharmacokinetic standpoint31.

Two phase II in elderly NSCLC patients treated with oral VRL as single agent in first line have been recently conducted. In the trial by Gridelly et al12, a total of 56 elderly patients ≥70 were recruited starting with 60 mg/m² once a week for three weeks (first cycle), followed by 80 mg/m² once a week until disease progression or development of unacceptable toxicity. Treatment was well tolerated with neutropenia grade 3 or 4 in 20% and 30% respectively and febrile neutropenia in 2% of patients. Six partial responses (11%) and 25 stable disease responses were recorded, with a disease control rate of 55%. Median overall survival was 8.2 months (95% confidence interval 6.2-11.3). The clinical benefit response rate was 31% on 32 evaluable patients. The second
trial was carried by Kanard et al\(^\text{33}\), with 58 evaluable patients \(\geq 65\) years with PS (ECOG) 0 or 1, in 88\% and PS 2 in only 12\% of patients. Oral VRL 60 mg/m\(^2\) per week was prescribed weekly as first-line therapy and no patients increased to 80 mg/m\(^2\). The response rate was of 3.4\% (95\% CI: 0.4-11.9\%). Median progression-free survival was 3.5 months (95\% CI: 2.2-5.4 months), and median overall survival was 7.5 months (95\% CI: 5-12 months).

Based on this collective background, we conducted this study of oral VRL as single agent in first-line advanced NSCLC in elderly patients more than 70 years. The dose-adjustment approach was aimed to optimize the haematological tolerance of the patient, while maintaining the efficacy reported for intravenous VRL. We did not perform lung cancer symptom scale quality of life data, but in the trial by Kanard et al\(^\text{33}\), patients appeared to favor oral chemotherapy at baseline, and they continued to favor it even after 1 month. We show the results of our low size patient recruitment, with an overall response of 13\% and with a median follow-up was 4 months (range, 1-9 months), the median survival time (MST) and median progression-free survival had not been reached; with 66\% of patients lived until date. Of course, this data are bias for the low time of follow-up, and several patients continue with chemotherapy. The efficacy data from our trial are equivalent compared with the results in the trial by Gridelly et al\(^\text{32}\), but superior respect the data showed by Kanard et al\(^\text{33}\). Probably this difference and the fact that there were only two episodes of severe leukopenia in that trial, suggests that a dose escalation strategy might have improved tumor response rates in the elderly trial reported here. Almost, one of the conclusions were that future studies with oral VRL in this population of patients might consider incorporating a dose escalation strategy in conjunction with careful toxicity monitoring.

In our sample, treatment with oral VRL in elderly patients was well tolerated, and there were no toxic deaths. No grade 4 toxicities were observed, and grade 3 toxicities were infrequent, exclusively neutropenia in 2 patients and asthenia in other 2 patients. Rest of toxicities were grade 1 or 2. This findings contrast with the two reports previously commented. In the trial by Kanard et al\(^\text{31}\), in which most patients had PS < 2, the limit of age was 65 years, and no patients increased dose to 80 mg/m\(^2\), however non-haematological toxicity was higher compared with our study. They had with five patients had grade 5 events, which included a fatal arrhythmia, cerebral vascular accident, a suicide, an acute exacerbation of chronic obstructive pulmonary disease with a possible infection, and an embolic event. Overall, seven patients had a grade 4 event as their most severe adverse event, and 21 patients had a grade 3 event as their most severe adverse event, although only two events of grade 4 neutropenia. In the trial by Gridelly et al\(^\text{32}\), haematological toxicity was higher with neutropenia grade 3 or 4 in 20\% and 30\% respectively. Again, probably this low percentage of toxicity in our trial may be partially explained by the low size of our sample.

Conclusions

Oral VRL appears to be a reasonable alternative to intravenous VRL, both in terms of activity and tolerability, in advanced, elderly NSCLC patients. Optimal schedule even in this population would be the same protocol than younger patients: starting with 60 mg/m\(^2\)/week; If during this phase, no grade 4 neutropenia or no more than one episode of grade 3 neutropenia occurred, the dose should be increased to 80 mg/m\(^2\) in subsequent administrations. We will follow the inclusion of patients in this protocol.

References

tumour activity of Navelbine. Semin Oncol 1989;16(suppl 4):15-20


Correspondence:
Manuel Cobo-Dols, MD
Sección de Oncología Médica
Pabellón A, 3ª planta derecha
Secretaría de Oncología Médica
Hospital Regional Universitario Carlos Haya
Avda. Carlos Haya, s/n
E-29010 Málaga (Spain)
mangel.cboodols@yahoo.es
manuelcobo.dols@juntadeandalucia.es